Science 37 Public Company (Nasdaq:SNCE)

Primary contact

🚀 Merged with LifeSci Acquisition II Corp. on May 7, 2021. in a SPAC deal worth $1.05B, raising $250M in the process.
Science 37 enables universal access to clinical research, making it easier for patients and providers to participate and accelerating the development of new and innovative treatments. The company's Decentralized Clinical Trial Operating System (DCT OS) is made to enable workflow orchestration, evidence generation and data harmonization on a unified, seamless platform — configurable to enable any study and fused with our expansive networks of telemedicine investigators, mobile nurses, remote coordinators, patient communities and connected devices. Science 37 has conducted more decentralized, interventional trials than any other company, using an expansive, in-house network of telemedicine investigators and home-health nurses.
Primary contact

Funding 💰

Total $147.5M
Select investors Mubadala Investment Company, Sanofi Ventures, Redmile Group, Lux Capital, Amgen, Novartis, GV, Glynn Capital Management
Last update: September 4, 2021